cFos Mediates cAMP-Dependent Generation of ROS and Rescue of Maturation Program in Retinoid-Resistant Acute Promyelocytic Leukemia Cell Line NB4-LR1

PLoS ONE

Volumn 7, Issue 11, 2012, Pages

  Carrier, Jean Luc ^a,b   Javadi, Pasha ^a,b   Bourrier, Emilie ^a,b   Camus, Céline ^a,b   Ségal Bendirdjian, Evelyne ^a,b   Karniguian, Aïda ^a,b  

^a INSERM   (France)

^b UNIVERSITÉ PARIS DESCARTES   (France)

Author keywords

[No Author keywords available]

Indexed keywords

CYCLIC AMP; PROTEIN C FOS; REACTIVE OXYGEN METABOLITE; RETINOID; RNA; SMALL INTERFERING RNA;

ALTERNATIVE RNA SPLICING; ARTICLE; CELL DIFFERENTIATION; CELL MATURATION; CONTROLLED STUDY; EFFECTOR CELL; EPIGENETICS; GENE MUTATION; GENE SILENCING; HUMAN; HUMAN CELL; LEUKEMIA CELL; NEUTROPHIL; ONCOGENE C FOS; PROMYELOCYTIC LEUKEMIA; RNA INTERFERENCE; RNA SPLICING;

ALTERNATIVE SPLICING; ANTIGENS, CD44; CELL LINE, TUMOR; CELL MEMBRANE; CYCLIC AMP; DNA PRIMERS; DRUG RESISTANCE, NEOPLASM; EPIGENESIS, GENETIC; EXONS; GENETIC VARIATION; HUMANS; NEUTROPHILS; PROTO-ONCOGENE PROTEINS C-FOS; REACTIVE OXYGEN SPECIES; RETINOIDS; RNA INTERFERENCE; RNA, MESSENGER; TIME FACTORS;

EID: 84870359489     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0050408     Document Type: Article

References (32)

1. Lanotte M, Martin-Thouvenin V, Najman S, Balerini P, Valensi F, et al. (1991) NB4, a maturation inducible cell line with t(15;17) marker isolated from a human acute promyelocytic leukemia (M3). Blood 77: 1080-1086.
2. Kamashev D, Vitoux D, De The H, (2004) PML-RARA-RXR oligomers mediate retinoid and rexinoid/cAMP cross-talk in acute promyelocytic leukemia cell differentiation. J Exp Med 199: 1163-1174.
3. Altucci L, Rossin A, Hirsch O, Nebbioso A, Vitoux D, et al. (2005) Rexinoid-triggered differentiation and tumor-selective apoptosis of acute myeloid leukemia by protein kinase A-mediated desubordination of retinoid X receptor. Cancer Res 65: 8754-8765.
4. Duprez E, Lillehaug JR, Naoe T, Lanotte M, (1996) cAMP signalling is decisive for recovery of nuclear bodies (PODs) during maturation of RA-resistant t(15;17) promyelocytic leukemia NB4 cells expressing PML-RAR alpha. Oncogene 12: 2451-2459.
5. Benoit G, Roussel M, Pendino F, Segal-Bendirdjian E, Lanotte M, (2001) Orchestration of multiple arrays of signal cross-talk and combinatorial interactions for maturation and cell death: another vision of t(15;17) preleukemic blast and APL-cell maturation. Oncogene 20: 7161-7177.
6. Roussel MJ, Lanotte M, (2001) Maturation sensitive and resistant t(15;17) NB4 cell lines as tools for APL physiopathology: nomenclature of cells and repertory of their known genetic alterations and phenotypes. Oncogene 20: 7287-7291.
7. Guillemin MC, Raffoux E, Vitoux D, Kogan S, Soilihi H, et al. (2002) In vivo activation of cAMP signaling induces growth arrest and differentiation in acute promyelocytic leukemia. J Exp Med 196: 1373-1380.
8. Lo Coco F, (1999) Development and overcoming of ATRA resistance in acute promyelocytic leukemia. Haematologica 84: 961-962.
9. de The H, Chen Z, (2010) Acute promyelocytic leukaemia: novel insights into the mechanisms of cure. Nat Rev Cancer 10: 775-783.
10. Abecassis I, Maes J, Carrier JL, Hillion J, Goodhardt M, et al. (2008) Re-expression of DNA methylation-silenced CD44 gene in a resistant NB4 cell line: rescue of CD44-dependent cell death by cAMP. Leukemia 22: 511-520.
11. Strahl BD, Allis CD, (2000) The language of covalent histone modifications. Nature 403: 41-45.
12. Thomson S, Clayton AL, Mahadevan LC, (2001) Independent dynamic regulation of histone phosphorylation and acetylation during immediate-early gene induction. Mol Cell 8: 1231-1241.
13. Nowak SJ, Corces VG, (2004) Phosphorylation of histone H3: a balancing act between chromosome condensation and transcriptional activation. Trends Genet 20: 214-220.
14. Duprez E, Ruchaud S, Houge G, Martin-Thouvenin V, Valensi F, et al. (1992) A retinoid acid 'resistant' t(15;17) acute promyelocytic leukemia cell line: isolation, morphological, immunological, and molecular features. Leukemia 6: 1281-1287.
15. Ruchaud S, Duprez E, Gendron MC, Houge G, Genieser HG, et al. (1994) Two distinctly regulated events, priming and triggering, during retinoid-induced maturation and resistance of NB4 promyelocytic leukemia cell line. Proc Natl Acad Sci U S A 91: 8428-8432.
16. Bendall LJ, Bradstock KF, Gottlieb DJ, (2000) Expression of CD44 variant exons in acute myeloid leukemia is more common and more complex than that observed in normal blood, bone marrow or CD34+ cells. Leukemia 14: 1239-1246.
17. Legras S, Gunthert U, Stauder R, Curt F, Oliferenko S, et al. (1998) A strong expression of CD44-6v correlates with shorter survival of patients with acute myeloid leukemia. Blood 91: 3401-3413.
18. Goodison S, Yoshida K, Churchman M, Tarin D, (1998) Multiple intron retention occurs in tumor cell CD44 mRNA processing. Am J Pathol 153: 1221-1228.
19. Vela E, Roca X, Isamat M, (2006) Identification of novel splice variants of the human CD44 gene. Biochem Biophys Res Commun 343: 167-170.
20. Yu Q, Toole BP, (1996) A new alternatively spliced exon between v9 and v10 provides a molecular basis for synthesis of soluble CD44. J Biol Chem 271: 20603-20607.
21. Bemmo A, Dias C, Rose AA, Russo C, Siegel P, et al. (2010) Exon-level transcriptome profiling in murine breast cancer reveals splicing changes specific to tumors with different metastatic abilities. PLoS One 5: e11981.
22. Hayes GM, Dougherty ST, Davis PD, Dougherty GJ, (2004) Molecular mechanisms regulating the tumor-targeting potential of splice-activated gene expression. Cancer Gene Ther 11: 797-807.
23. Shafarenko M, Amanullah A, Gregory B, Liebermann DA, Hoffman B, (2004) Fos modulates myeloid cell survival and differentiation and partially abrogates the c-Myc block in terminal myeloid differentiation. Blood 103: 4259-4267.
24. Jack GD, Zhang L, Friedman AD, (2009) M-CSF elevates c-Fos and phospho-C/EBPalpha(S21) via ERK whereas G-CSF stimulates SHP2 phosphorylation in marrow progenitors to contribute to myeloid lineage specification. Blood 114: 2172-2180.
25. Ohkubo Y, Arima M, Arguni E, Okada S, Yamashita K, et al. (2005) A role for c-fos/activator protein 1 in B lymphocyte terminal differentiation. J Immunol 174: 7703-7710.
26. Lord KA, Abdollahi A, Hoffman-Liebermann B, Liebermann DA, (1993) Proto-oncogenes of the fos/jun family of transcription factors are positive regulators of myeloid differentiation. Mol Cell Biol 13: 841-851.
27. Asagiri M, Takayanagi H, (2007) The molecular understanding of osteoclast differentiation. Bone 40: 251-264.
28. Grigoriadis AE, Wang ZQ, Cecchini MG, Hofstetter W, Felix R, et al. (1994) c-Fos: a key regulator of osteoclast-macrophage lineage determination and bone remodeling. Science 266: 443-448.
29. Boyle WJ, Simonet WS, Lacey DL, (2003) Osteoclast differentiation and activation. Nature 423: 337-342.
30. Han B, Rorke EA, Adhikary G, Chew YC, Xu W, et al. (2012) Suppression of AP1 transcription factor function in keratinocyte suppresses differentiation. PLoS One 7: e36941.
31. Lai HC, Wu MJ, Chen PY, Sheu TT, Chiu SP, et al. (2011) Neurotrophic effect of citrus 5-hydroxy-3,6,7,8,3′,4′-hexamethoxyflavone: promotion of neurite outgrowth via cAMP/PKA/CREB pathway in PC12 cells. PLoS One 6: e28280.
32. Mullenbrock S, Shah J, Cooper GM, (2011) Global expression analysis identified a preferentially nerve growth factor-induced transcriptional program regulated by sustained mitogen-activated protein kinase/extracellular signal-regulated kinase (ERK) and AP-1 protein activation during PC12 cell differentiation. J Biol Chem 286: 45131-45145.